Sign In
Buy AZN
$183.02
+2.00 (+1.10%)
At Close: Jun 24, 2026
Ionis (IONS) Partner Wraps Up Cardiovascular Study Enrollment
02:40pm, Thursday, 21'st Jul 2022 Zacks Investment Research
Ionis' (IONS) partner, Novartis completes enrolling patients in a phase III study on pelacarsen for treating cardiovascular disease due to elevated Lp(a) levels. Data from this study is expected in 20
AstraZeneca (AZN) Enhertu Receives EU Nod for Expanded Use
03:08pm, Wednesday, 20'th Jul 2022 Zacks Investment Research
AstraZeneca (AZN) and partner Daiichi Sankyo's cancer drug, Enhertu, receives EU approval for use in adults with unresectable or metastatic HER2-positive breast cancer.
AstraZeneca (AZN) Enhertu Receives EU Nod for Expanded Use
12:25pm, Wednesday, 20'th Jul 2022
AstraZeneca (AZN) and partner Daiichi Sankyo's cancer drug, Enhertu, receives EU approval for use in adults with unresectable or metastatic HER2-positive breast cancer.
Why Moderna Stock Bumped Higher Today
07:22pm, Tuesday, 19'th Jul 2022 The Motley Fool
The company wins yet another approval for its coronavirus vaccine.
Merck & AstraZeneca Partnered Lynparza Fails In Late-Stage Colorectal Cancer Study
01:15pm, Tuesday, 19'th Jul 2022
Merck & Co Inc (NYSE: MRK) will stop for futility the Phase 3 LYNK-003 trial of Lynparza with or without bevacizumab for unresectable or metastatic colorectal cancer who have not progressed followi
AstraZeneca: Lifeline Amid Double-Digit Inflation
03:55am, Sunday, 17'th Jul 2022
AstraZeneca's operating income was $2,808 million in Q1 2022, up 49.5% QoQ. At the end of June 2022, the CHMP recommended the approval of Enhertu and Lynparza in the EU.
UnitedHealth Group (UNH) Q2 Earnings Beat, Hikes '22 EPS View
03:34pm, Friday, 15'th Jul 2022 Zacks Investment Research
UnitedHealth Group's (UNH) second-quarter results gain from revenue growth stemming from solid segmental contributions and membership growth. A raised 2022 EPS view remains noteworthy.
Merck (MRK) Buys Rights to Mid-Stage Prostate Cancer Candidate
02:46pm, Thursday, 14'th Jul 2022 Zacks Investment Research
Merck (MRK) is set to make an upfront payment of $290 million to Orion for co-development and co-commercialization rights to ODM-208.
Beat The Bear With 3 Tools: Dividends, Dividends And Dividends
12:28pm, Sunday, 10'th Jul 2022 Investing.com
Pharma Stock Roundup: AZN's Small Cancer Firm Buyout, FDA Updates for PFE, RHHBY
03:34pm, Friday, 08'th Jul 2022 Zacks Investment Research
FDA grants priority review to Roche's (RHHBY) BLA for Lunsumio. AstraZeneca (AZN) announces a small acquisition. Pfizer (PFE) files NDA for Paxlovid.
Merck's Oncology Business Will Help It Crush the Bear Market
02:45pm, Thursday, 07'th Jul 2022 The Motley Fool
The drugmaker is defying the stock market sell-off right now.
Company News for Jul 6, 2022
01:05pm, Wednesday, 06'th Jul 2022 Zacks Investment Research
Companies in The News Are: F, STLA, AZN, CVX.
AstraZeneca (AZN) to Buy TeneoTwo, Boost Hematology Pipeline
02:16pm, Tuesday, 05'th Jul 2022 Zacks Investment Research
AstraZeneca's (AZN) acquisition of TeneoTwo is set to add an early-stage T-cell engager to AZN's pipeline. The transaction is likely to close by third-quarter 2022.
3rd-Quarter Clinical Trial Data Could Shake Up Pharma Stocks
11:43am, Tuesday, 05'th Jul 2022
Health care investors would be wise to keep tabs on the results of numerous drug trials scheduled to be revealed in the third quarter. Trial data can impact the stock price of a pharmaceutical company
AstraZeneca (AZN) to Buy TeneoTwo, Boost Hematology Pipeline
11:38am, Tuesday, 05'th Jul 2022
AstraZeneca's (AZN) acquisition of TeneoTwo is set to add an early-stage T-cell engager to AZN's pipeline. The transaction is likely to close by third-quarter 2022.
